Eloxx Pharmaceuticals IncOOTC ELOX Stock Report

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2012-11-23. The firm is focused on ribosome modulation, by leveraging its TURBO-ZM chemistry technology platform and its library of aminoglycosides in developing oral small molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs), for the treatment of rare and ultra-rare premature stop codon diseases and ribosomal mutations. The firm's lead product candidate, ELX-02, is a small molecule designed to restore production of full-length functional proteins. ELX-02 is an investigational ERSG designed based on aminoglycoside antibiotics, such as gentamicin, with increased selectivity for the eukaryotic ribosome. The firm's preclinical programs are focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.